<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182646</url>
  </required_header>
  <id_info>
    <org_study_id>AIG-G/IGBFLP</org_study_id>
    <nct_id>NCT04182646</nct_id>
  </id_info>
  <brief_title>Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>A Clinical Study on the Effect of Adjustable Intragastric Balloon in Obese Patients With Non Alcoholic Fatty Liver Disease(NAFLD) or Non-Alcoholic Steatohepatitis (NASH) With or Without Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Institute of Gastroenterology, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asian Institute of Gastroenterology, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aims and objectives:

      The Investigator aimed to evaluate effect of adjustable intra gastric balloon on
      non-alcoholic fatty liver disease/non alcoholic steatohepatitis (NAFLD/NASH) with or without
      diabetes mellitus, who have failed to achieve &gt;10% of total body weight with lifestyle
      interventions and pharmacotherapy for weight loss.

      The Investigator will evaluate NASH parameters such as NASH activity score(NAS), liver
      function tests along with weight loss and change in glycaemic control and changes in hormonal
      activity.

      Sample size:

      Based on previous study, to achieve median reduction of 40% in NAS score with 80% power and
      0.05 as type 1 error; total sample size required is 36 cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Nonalcoholic fatty liver disease (NAFLD) is an emerging major health problem worldwide which
      affects a significant proportion of the western population and there is gradual spread of
      this epidemic to south-east Asian countries. NAFLD encompasses two entities: Non-alcoholic
      fatty liver (NAFL) and Non-alcoholic steatohepatitis (NASH). NAFL is defined as the evidence
      of hepatic steatosis without inflammation either by raised liver enzymes, imaging or by
      histology in individuals without significant alcohol consumption in whom secondary causes of
      steatosis are absent. NASH on the other hand, is characterized by the presence of both
      steatosis and inflammation with evidence of hepatocyte injury in the form of ballooning with
      or without fibrosis.

      Materials and Methods:

      Study Enrollment:

      Participants with diabetes attending the liver and bariatric clinic of the institute who have
      a Body Mass Index (BMI) &gt; 27.5 Kg/m2 would be screened for eligibility. At first diagnosis of
      NAFLD / NASH, participants would be advised as per protocol to first attend the department of
      dietetic and nutrition for a low calorie diet and would also be advised for life style
      modifications for the next 6 months. They would be explained that the target weight loss
      would be 10% of the base weight. The exercise program would include a combination of aerobic,
      resistive and core building exercises. The participants would also be screened for secondary
      causes of obesity like hypothyroidism, hypercortisolism etc. Co morbidities like
      hypertension, hypothyroidism etc. would be screened and treated accordingly as per protocol.
      Secondary causes of NAFLD/ NASH would be ruled out by adequate history of intake of any
      steatogenic drugs as well as ruling out other conditions like Wilson disease, Autoimmune
      hepatitis, Viral hepatitis etc. Baseline investigations would include complete hemogram ,
      liver function tests, anti-nuclear antibodies, anti-smooth muscle antibodies,
      anti-liver-kidney-microsomal antibodies, serum copper, serum ceruloplasmin, thyroid
      stimulating hormone , 8 am serum cortisol, fasting insulin, hepatitis B surface antigen and
      anti-hepatitis C antibody screening. Additional tests would include renal function tests, gut
      hormones assessment, electrocardiography, ultrasonography of the abdomen with acoustic
      resonance fibrosis imaging (ARFI) or a fibro scan. Additional tests like CT abdomen or high
      density proton fraction estimation by Magnetic resonance imaging would be done wherever
      clinically indicated. A liver biopsy would be advised to assess the presence of NASH and
      grading of fibrosis would be done by the interventional radiologist and reported by expert
      pathologist.

      Follow-up:

      At the 3rd month visit, participants would be re motivated and re-explained the weight loss
      importance and the lifestyle and dietary changes for resolution of NAFLD/ NASH. At this
      stage, they would be introduced the concept of endoscopic intragastric balloon as a
      prospective treatment as a part of the clinical study.

      At the 6-month visit, if the participants has failed to lose at least 7% weight despite
      adequate exercise and lifestyle and dietary changes, then they would be offered to be
      enrolled in this clinical study. Alternative therapies including bariatric surgery and
      continuing with life style modifications and medications would be explained.

      Method of Balloon Insertion and Post Procedure Care:

      All participants will undergo upper gastrointestinal endoscopy using conscious sedation with
      or without an anaesthetist using one or more of the following medications - Propofol or
      midazolam.

      The Spatz balloons are usually inflated with a mean 450ml (400-500ml) of normal saline with
      the addition of 2-3 ml of a 1% solution of Methylene Blue. After the 5th post-procedure day,
      a progressive full liquid to soft solid 1,200-1,400 kcal diet will be started. At one month
      follow up with principal investigator will be done. Participants who are intolerant to the
      balloon could be adjusted downward by 50-100 ml. Participants with one or more of the
      following were offered upward adjustments of the balloon volume (100-200 ml at the discretion
      of the endoscopist): weight loss plateau; lack of balloon effect; ability to overeat without
      resultant symptoms (any of the following: nausea, vomiting, bloating, eructation, abdominal
      pain, acid reflux symptoms). After 12 months of placement, the balloon will be deflated by
      aspiration via catheter and then retrieved under endoscopic/fluoroscopic guidance.

      The data will be collected in excel sheets and later analysed using statistical analysis
      software. Any adverse effects would be noted and any serious adverse effects like severe
      pain, severe diarrhoea or catheter impaction which has been reported in less than 1%
      participants would be reported and adequate measures will be taken.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year which have capability for decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in NAFLD activity Score</measure>
    <time_frame>6 months</time_frame>
    <description>The 'NAFLD activity score' (NAS) is the most widely used histological grading and staging system for NAFLD. It is a histological scoring system addressing the full spectrum of NAFLD. It includes steatosis, hepatocellular ballooning, lobular inflammation, fibrosis, and the absence of lipogranulomas. In our study, liver histology was assessed by a single pathologist before and after treatment.
Steatosis is graded as 0, 1, 2 and 3 depending on steatosis in hepatocytes.Lobular inflammation is graded as 0,1,2 and 3 depending on number of foci of inflammation per 20x field. Hepatocellular ballooning is graded as 0,1 and 2 depending on amount of ballooning. Fibrosis is graded as 0,1,2,3 and 4 depending on level of fibrosis. A composite score is calculated by addition on individual scores from steatosis, hepatocellular ballooning, lobular inflammation and fibrosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage of Total Body Weight Loss (%TBWL) 6 months After Balloon Removal</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of total body weight loss (%TBWL) will be calculated as 6 months after removal of balloon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver enzymes</measure>
    <time_frame>6 months</time_frame>
    <description>Liver enzymes are non-invasive markers of liver injury. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) change will be studied in comparison with baseline levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with &gt;= 25% Excess Body Weight Loss at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of patients achieving more than 25% Excess weight loss at 6 months will be studied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glycemic control</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in glycemic control will be assessed by change in HbA1c after 6 months of balloon removal will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spartz Balloon</intervention_name>
    <description>The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants (age 18- 65) diagnosed to have NAFLD / NASH as per imaging and
             histological criteria of American Association for Study of Liver Diseases (AASLD) with
             or without Diabetes Mellitus and who have failed the non-invasive approach to weight
             loss within the last 6 months. This would include patients who have failed to lose at
             least 10% of their base weight with dietary and lifestyle changes along with
             pharmacotherapy.

          2. Patients with BMI &gt; 27.5 kg/m2 who are unable to tolerate exercise program for weight
             loss.

          3. Patients with BMI &gt; 32.5 Kg/m2 who have NAFLD / NASH but are not willing for bariatric
             surgery.

        Exclusion Criteria:

          1. Previous history of gastric or bariatric surgery

          2. Current or recent (within 6 months) gastric or duodenal ulcers

          3. Cirrhosis patients with clinically significant portal hypertension defined as Hepatic
             Venous Pressure Gradient (HVPG) &gt; 12 or recent variceal or Portal hypertensive
             gastropathy related bleed within the last 3 months

          4. Presence of inflammatory disease of the gastrointestinal tract including esophagitis,
             gastric ulceration, duodenal ulceration, cancer or specific inflammation such as
             Crohn's disease.

          5. A large hiatal hernia or &gt;5 cm hernia or â‰¤5 cm with associated severe or intractable
             gastro-esophageal reflux symptoms.

          6. Achalasia or any other severe motility disorder that may pose a safety risk during
             removal of the device.

          7. Any gastric space occupying lesions including polyps,

          8. Patients who are known to have or suspected to have an allergic reaction to materials
             contained in Adjustable balloon.

          9. Psychologically unstable patients or patients with known psychiatric illness.

         10. Patients unwilling to participate in an established medically-supervised diet and
             behaviour modification program, with routine medical follow-up.

         11. Patients receiving aspirin, anti-inflammatory agents, anticoagulants or other gastric
             irritants, not under medical supervision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rakesh Kalapala, DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Institute of Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh Kalapala, DNB</last_name>
    <phone>040 4244 4222</phone>
    <phone_ext>2000</phone_ext>
    <email>drrakesh.kalapala@aighospitals.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nitin Jagtap, DNB</last_name>
    <phone>040 4244 4222</phone>
    <phone_ext>2000</phone_ext>
    <email>docnits13@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohan Ramchandani, MBBS</last_name>
      <phone>04023378888</phone>
      <phone_ext>802</phone_ext>
      <email>ramchandanimohan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>January 18, 2020</last_update_submitted>
  <last_update_submitted_qc>January 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Institute of Gastroenterology, India</investigator_affiliation>
    <investigator_full_name>Rakesh K</investigator_full_name>
    <investigator_title>Consultant Gastroenterologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

